An FDA-registered 503B outsourcing facility for ImprimisRx has received a non-resident operating license from the state of California, the company announced in a press release.
ImprimisRx, a wholly owned subsidiary of Harrow Health, will now be able to provide its ophthalmic products to ophthalmologists, optometrists, surgery centers and hospitals in the state.
“The expected impact to ImprimisRx from this new license cannot be understated. While our business as a whole continues to grow nationally, we now expect California demand to significantly pick up and for California-specific sales
Uncategorized